Project Grant R03CA292132
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$161K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This federal Project Grant award, with an ID of R01CA294704, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic for the project "Radiation and Dendritic Cell Combination to Improve Immunotherapy Response in Intrahepatic Cholangiocarcinoma". The $610,890 award, effective September 1, 2024 through August 31, 2029, will support a two-part research study. The first aim is to assess the clinical efficacy of combining external beam...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $518,219 in funding to the University of Pittsburgh to conduct research aimed at deciphering the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a deadly form of liver cancer. The key objectives of this 5-year research project are to: Investigate the intertwined roles of the nuclear receptors FXR and CAR in promoting the malignant transformation of hepatocytes...
This Project Grant award of $671,384, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), aims to develop new and novel biomarkers for cholangiocarcinoma (CCA), a highly lethal form of liver cancer, based on glycan changes observed in CCA tissue and serum samples. The primary awardee, the Medical University of South Carolina, will lead the research effort to identify glycan biomarkers that can differentiate CCA from healthy or other diseased...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $564,900.00 to Mayo Clinic to support research aimed at "EXPLOITING VIRAL TROPISM TO TARGET CANCER-ASSOCIATED FIBROBLASTS IN INTRAHEPATIC CHOLANGIOCARCINOMA". The award period runs from September 1, 2024 to August 31, 2026. Mayo Clinic, a renowned non-profit academic medical center, will leverage its expertise in cancer biology, drug development,...
The National Cancer Institute (NCI) awarded a $2,489,032 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The 5-year award, effective August 1, 2025, will support three highly integrated research projects focused on determining the roles, regulation, and underlying mechanisms of lipid metabolism in ferroptosis, a form of iron-dependent cell death, and exploring novel cancer therapeutic approaches based on these...
This $1,224,644 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to dissect a novel tumor-promoting axis involving the immune checkpoint protein B7-H4 in intrahepatic cholangiocarcinoma (CCA), a highly desmoplastic and deadly form of bile duct cancer. The 5-year award, effective August 2024, will leverage the awardee's (Icahn School of Medicine at Mount Sinai) expertise and preliminary data to: 1) elucidate the molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,000.00 to Mayo Clinic to conduct research aimed at enhancing the effectiveness of immune checkpoint blockade (ICB) immunotherapy for renal cell carcinoma (RCC). The project seeks to demonstrate that disrupting the ubiquitination or phosphorylation of the RIPK1 protein in RCC tumor cells can increase their susceptibility to killing by T cells in a TNF-dependent manner, thereby...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding how different forms of cell death, particularly programmed necrosis, can alter the immune response and impact tumor growth. The $568,538 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a 5-year study to investigate the role of the cytokine interleukin-1 alpha in mediating immune suppression and promoting...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $219,491 to the Mayo Clinic Jacksonville to conduct research on the epigenetic regulation of T cell metabolism and immune functions by the SIRT6 protein. The research aims to understand how SIRT6 impacts the metabolic activity and effector functions of tumor-reactive T cells, with the goal of identifying ways to boost T cell metabolism and enhance cancer immunotherapies. The study will...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...